Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional)
ID: 341931Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/341931

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-213.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional) program, aimed at supporting large-scale research initiatives that address critical questions related to aging. This funding opportunity encourages multidisciplinary collaboration among higher education institutions, nonprofits, and government entities, focusing on projects that integrate various components such as coordinating centers and clinical sites, particularly in areas like Alzheimer’s disease and health disparities. There is no limit on application budgets, but they must accurately reflect project needs, with a maximum project period of five years. Interested applicants should note that the submission deadline for the first round is January 25, 2023, and can find further details and application instructions at the provided NIH link or by contacting the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-213-Full-Announcement.html
    PAR-22-213.html
    The Department of Health and Human Services is inviting applications for funding under the Complex Integrated Multi-Component Projects in Aging Research program (U19 Clinical Trial Optional). This opportunity, reissued as PAR-22-213, supports large-scale research projects involving integrated components addressing critical questions in aging. Targeted applicants include higher education institutions, nonprofits, and government entities, promoting multidisciplinary collaboration. The FOA seeks projects with various components, such as coordinating centers and clinical sites, focusing on aging-related studies, including Alzheimer’s disease, inter-organ communication, and health disparities. The funding mechanism emphasizes the necessity of cross-institutional integration to ensure proposed projects leverage diverse expertise. While there is no limit on application budgets, they must reflect actual project needs, and a maximum project period is set at five years. Key dates outline submission deadlines, with the first round on January 25, 2023. The document underscores compliance with strict application instructions, urging early submission for error corrections. This initiative highlights the NIH's commitment to advancing aging research through innovative, large-scale, and collaborative approaches.
    Similar Opportunities
    NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced the NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) to support investigator-initiated multi-site interventional clinical trials focused on aging-related research. This funding opportunity aims to foster innovative biomedical and behavioral studies that address the complexities of aging, particularly in populations with multiple chronic conditions and polypharmacy. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal governments, with an emphasis on rigorous trial designs that ensure ethical considerations and participant diversity. Interested parties should note that the application deadline is January 7, 2026, and further details can be found at the provided NIH grants link, with inquiries directed to grantsinfo@nih.gov.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multidisciplinary research on HIV/AIDS and aging through the R21 Exploratory/Developmental Research Grant program. This initiative invites applications that aim to enhance the understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, with specific objectives to improve prevention, testing, treatment strategies, and management of HIV-related health issues in diverse populations, particularly older adults aged 70 and above. The grant provides funding of up to $275,000 for a two-year period, with key submission dates starting April 4, 2024, and a closing date for applications set for January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced the NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) to support the implementation of investigator-initiated multi-site interventional clinical trials focused on aging research. These trials must be hypothesis-driven and aim to address significant health challenges faced by populations aged 65 and older, particularly concerning multimorbidity and polypharmacy. This funding opportunity is crucial for advancing scientific understanding and improving health outcomes for older adults, with applications accepted for new, renewal, and resubmission proposals, and no budget limits as long as they align with project needs. Interested applicants can find more information and submit their proposals by January 7, 2026, and should direct inquiries to grantsinfo@nih.gov.
    Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)" aimed at enhancing research on the intersection of HIV and aging. The program seeks applications that focus on improving the understanding of biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, as well as developing better methods for testing, preventing, and managing HIV-related health issues among older populations. This initiative is particularly significant given the projected increase in the prevalence of HIV among older adults, which is expected to rise from 53% to over 70% by 2030, highlighting the urgent need to address the complex challenges associated with aging and HIV. Interested applicants can submit proposals until January 7, 2027, with no budget limits as long as they align with project needs; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-354.html.
    Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Multidisciplinary Studies of HIV/AIDS and Aging," inviting applications for research that explores the intersection of HIV and aging. The primary objectives of this grant are to enhance understanding of the biological, clinical, and socio-behavioral aspects of aging in individuals living with HIV, as well as to improve strategies for testing, preventing, and treating HIV and managing related health complications. This funding opportunity is significant for advancing health interventions for older adults affected by HIV, with eligible applicants including a wide range of institutions such as higher education entities, community organizations, and tribal governments. Interested parties should note that the application deadline is May 7, 2027, and can find further details and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-091.html.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Multidisciplinary Studies of HIV/AIDS and Aging," aimed at exploring the intersection of HIV and aging. This initiative seeks to enhance understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, while also improving strategies for testing, prevention, and treatment of HIV-related health complications. Given the increasing number of older adults living with HIV, this research is crucial for addressing public health challenges and improving healthcare delivery across diverse populations. The funding supports exploratory research under the R21 mechanism, with a maximum budget of $275,000 for two years, and applications are due between May 2025 and January 2027. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-355.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Facilitating Preclinical and Early Phase Human Studies for New Therapeutics (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for facilitating preclinical and early phase human studies for new therapeutics, specifically targeting aging-related conditions. This initiative aims to advance T1 translational aging research, focusing on therapeutics that progress from preclinical stages to first-in-human trials, addressing conditions such as sarcopenia and heart failure with preserved ejection fraction (HFpEF). The funding opportunity, categorized under health-related activities, will utilize the UG3/UH3 Cooperative Agreement mechanism, with an estimated total program funding of $2.5 million. Interested applicants should prepare to submit their applications by fall 2024, with the NOFO expected to be published in summer 2024 and awards anticipated by July 2025.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) to support the preclinical and early-stage clinical development of innovative drug candidates aimed at preventing or treating Alzheimer's disease (AD). This funding opportunity focuses on activities such as medicinal chemistry, pharmacokinetics, formulation development, and initial Phase I clinical testing, addressing the urgent public health challenge posed by AD, which currently affects approximately 6.7 million individuals in the U.S. Eligible applicants include a diverse range of organizations, with a funding ceiling of $1.5 million per year, and the application process is set to begin in January 2025, with a closing date of November 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Healthcare for Older Adults from Populations that Experience Health Disparities" under the R01 Clinical Trial Optional grant program. This initiative aims to enhance the science and implementation of healthcare research focused on older adults from populations facing health disparities, specifically targeting improvements in screening, diagnostic, and clinical care guidelines, as well as fostering shared decision-making between clinicians and patients. The research is particularly significant for addressing the unique health challenges encountered by older adults from racial and ethnic minorities and underserved communities, emphasizing innovative care solutions that consider social determinants of health. Interested applicants can find more information and apply through the NIH Grants website, with the application opening on January 5, 2025, and a close date set for January 7, 2028. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.